769 Guselkumab, an Il-23p19 Subunit-Specific Monoclonal Antibody, Binds Cd64+ Myeloid Cells and Potently Neutralizes Il-23 Produced From the Same Cells

Abreu, María T.; Atreya, Raja; Krueger, James G.; Eyerich, Kilian; Sachen, Kacey L.; Greving, C.; Hammaker, Deepa; Bao, Phuc; Lacy, Eilyn R.; Sarabia, Indra; Deming, Janise D.; Elloso, M. Merle; Ritchlin, Christopher T.; McInnes, Iain B.; Allez, Matthieu; Fourie, Anne M.

doi:10.1016/s0016-5085(23)01353-7

Gastroenterology

2023

DOI: 10.1016/s0016-5085(23)01353-7

|View full text |Cite

769 Guselkumab, an Il-23p19 Subunit-Specific Monoclonal Antibody, Binds Cd64+ Myeloid Cells and Potently Neutralizes Il-23 Produced From the Same Cells

María T. Abreu¹,

Raja Atreya²,

James G. Krueger³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Danese,

Panaccione,

Feagan

et al. 2024

The Lancet Gastroenterology & Hepatology

View full text Add to dashboard Cite

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Danese,

Panaccione,

Feagan

et al. 2024

The Lancet Gastroenterology & Hepatology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

769 Guselkumab, an Il-23p19 Subunit-Specific Monoclonal Antibody, Binds Cd64+ Myeloid Cells and Potently Neutralizes Il-23 Produced From the Same Cells

Cited by 1 publication

References 0 publications

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Contact Info

Product

Resources

About